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vist in Europe and Eovist in the USA) is a liver-speciﬁc magnetic
resonance imaging contrast agent that has up to 50% hepatobilia-
ry excretion in the normal liver. After intravenous injection,
Gd-EOB-DTPA distributes into the vascular and extravascular
spaces during the arterial, portal venous and late dynamic phases,
and progressively into the hepatocytes and bile ducts during the
hepatobiliary phase. The hepatocyte uptake of Gd-EOB-DTPA
mainly occurs via the organic anion transporter polypeptides
OATP1B1 and B3 located at the sinusoidal membrane and biliary
excretion via the multidrug resistance-associated proteins MRP2
at the canalicular membrane. Because of these characteristics,
Gd-EOB-DTPA behaves similarly to non-speciﬁc gadolinium che-
lates during the dynamic phases, and adds substantial informa-
tion during the hepatobiliary phase, improving the detection
and characterization of focal liver lesions and diffuse liver disease.
This information is particularly relevant for the detection of
metastases, and for the detection and characterization of nodular
lesions in liver cirrhosis, including early hepatocellular carcino-
mas. Finally, GD-EOB-DTPA-enhanced magnetic resonance imag-
ing may provide quantitative assessment regarding liver
perfusion and hepatocyte function in diffuse liver diseases. The
full potential of GD-EOB-DTPA-enhanced magnetic resonance
imaging has to be established further. It is already clear that
GD-EOB-DTPA-enhanced magnetic resonance imaging provides
anatomic and functional information in the setting of focal and
diffuse liver disease that is unattainable with magnetic resonance
imaging enhanced with non-speciﬁc contrast agents.Journal of Hepatology 20
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Magnetic resonance (MR) imaging has an important role in the
detection and characterization of focal and diffuse liver diseases.
Contrast agents improve the detection of focal liver lesions by
increasing the lesion-to-liver contrast. Depending on their phar-
macokinetics, contrast agents also improve the characterization
of focal and diffuse liver diseases by showing changes in the vascu-
lar, extracellular, or intracellular volumes, and by demonstrating
modiﬁcations in the transfer rates between these compartments,
including perfusion, endothelial permeability, extracellular diffu-
sion, hepatocytic uptake and biliary excretion [1]. These volumes
and transfer rates can be quantiﬁed at contrast-enhanced MR
imaging, which has thus the potential to offer imaging biomarkers
for the assessment of liver diseases [2].
In the liver, contrast agents are categorized into non-speciﬁc
agents that distribute into the vascular and extravascular extra-
cellular spaces (such as the linear gadopentetate dimeglumine
(Gd-DTPA), Magnevist, Bayer HealthCare, Berlin, Germany;
and the macrocyclic gadobutrol (Gd-DO3A-butrol), Gadovist,
Bayer HealthCare, and gadoterate dimeglumine (Gd-DOTA),
Dotarem, Guerbet, Aulnay-sous-Bois, France) and liver-speciﬁc
agents taken up by liver cells. These liver-speciﬁc agents are
either taken up by Kupffer cells (such as the superparamagnetic
iron oxide particles ferumoxides, Endorem, Guerbet; and
ferucarbotran, Resovist, Bayer HealthCare) or by hepatocytes
(such as gadolinium ethoxybenzyl dimeglumine or gadoxetate
dimeglumine (Gd-EOB-DTPA), Primovist in Europe and Eovist
in the USA, Bayer HealthCare; and gadobenate dimeglumine
(Gd-BOPTA), MultiHance, Bracco, Milan, Italy). Gd-EOB-DTPA
and Gd-BOPTA can be injected as an intravenous bolus and pro-
vide information regarding lesion vascularity in the early arte-
rial and venous phases and regarding hepatocyte presence and
function in the delayed hepatobiliary phase performed either
20 min (Gd-EOB-DTPA) or 60–120 min (Gd-BOPTA) after injec-
tion. With Gd-EOB-DTPA, approximately 50% of the adminis-
tered dose in the normal human liver is transported through
the hepatocytes and excreted into the bile, a proportion much
higher than that of Gd-BOPTA, which only has up to 5% hepa-
tobiliary excretion [3].12 vol. 57 j 421–429
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Fig. 1. Cellular pharmacology of Gd-EOB-DTPA. Following distribution in the
hepatic sinusoids and Disse spaces, GD-EOB-DTPA enters into hepatocytes
through the organic anion transporting polypeptides OATP1B1 and OATP1B3.
GD-EOB-DTPA exits through the ATP-dependent canalicular membrane multidrug
resistance protein MRP2. MRP3 and MRP4 are transporters located in the
sinusoidal membrane that may allow the efﬂux of GD-EOB-DTPA back to
sinusoids. The OATP are bidirectional transporters (¡). Transport through MRP2
is unidirectional (?) and MRP2 is regulated by retrieval from the membrane
(decreased bile efﬂux) and insertion (increased bile efﬂux) while the localization
of OATP never changes. Gd-EOB-DTPA is not metabolized within hepatocytes and
is excreted unchanged into bile.
ReviewThe percentage of the contrast agent that is not cleared by the
hepatobiliary system is excreted by glomerular ﬁltration in the
kidneys. The plasma half life of Gd-EOB-DTPA is approximately
56 min in subjects with normal hepatorenal function, which is
shorter compared to extracellular contrast agents (e.g. Gd-DTPA
96 min) [4]. A study by Gschwend et al. assessing the pharmaco-
kinetics and safety of Gd-EOB-DTPA in patients with renal failure,
hepatic failure or both showed that in patients with mild-to-
moderate hepatic impairment, renal excretion was increased to
compensate for hepatic impairment, and hepatic elimination
was increased in the case of renal impairment [5]. The pharmaco-
kinetic parameters of Gd-EOB-DTPA were markedly altered in
patients with end-stage renal disease requiring chronic hemodial-
ysis only, and theMR imaging signal enhancement of the liver was
decreased in the presence of Child C and bilirubin values >3 g/dl.Characteristics of Gd-EOB-DTPA
Gd-EOB DTPA is an amphipathic derivative of Gd-DTPA (Gd-DTPA
with a covalently bound lipophilic ethoxybenzyl moiety). It has a
molecular weight of 726 daltons and higher protein binding
capacity than Gd-DTPA (10% vs. 1.5%). This binding increases
the T1 relaxivity of Gd-EOB DTPA and resultant signal enhance-
ment in blood and liver compared to Gd-DTPA. It has been
reported that the T1 relaxivity of Gd-EOB-DTPA in water, rat
blood and rat liver at 20 MHz and 39 C is 5.3 L/mmol s, 11.2 L/422 Journal of Hepatology 201mmol s and 16.6 L/mmol s respectively, compared to a relatively
constant relaxivity of Gd-DTPA at 5 L/mmol s in the same condi-
tions [6,7]. This high relaxivity explains the lower clinical recom-
mended dose of Gd-EOB-DTPA, 0.025 mmol/kg vs. 0.1 mmol/kg
for Gd-DTPA and other non-speciﬁc gadolinium-based contrast
agents.
However, this low clinical dose of Gd-EOB-DTPA may lead to
lower enhancement of the aorta, liver and portal vein during
the arterial and venous phases as compared to non-speciﬁc gad-
olinium chelates at their recommended dose [8]. Moreover, the
injection volume of Gd-EOB-DTPA is smaller than that of non-
speciﬁc gadolinium agents. This small volume can result in acqui-
sition timing error and truncation artifacts in the arterial phase if
not properly timed. Using ﬂuoroscopic triggering with a low
injection rate of 1 ml/s to stretch the bolus or diluting the con-
trast with normal saline to 20 ml to enable a rapid injection rate
at 2 ml/s are suggested solutions [9–11]. Doubling the dose of
Gd-EOB-DTPA has also been suggested. In a study of patients
with cirrhosis and hepatocellular carcinomas (HCC), it has been
shown that doubling the dose improves the tumor-to-liver con-
trast during the arterial phase in all patients and during the hepa-
tobiliary phase in Child B patients [12].The clinical impact of this
policy in terms of lesion detection remains unknown.
Gd-EOB-DTPA is well tolerated with adverse events similar to
those reported with non-speciﬁc gadolinium chelates. Of 162
patients included in a phase III trial of Gd-EOB-DTPA injection,
a total of 11 (6.8%) patients reported a total of 21 adverse events.
These adverse events were assessed as: one deﬁnitely related,
ﬁve probably, seven possibly, one unlikely and seven not related
to the study drug. The most frequently reported adverse events of
deﬁnite, possible or probable relationship to the contrast agent
were nausea, vasodilatation, headache, taste perversion, and
injection site pain [13].
Gd-EOB-DTPA is an open-chain (linear) gadolinium chelate
that has a lower kinetic stability than macrocyclic gadolinium
chelates [14]. To the best of our knowledge, no case of nephro-
genic systemic ﬁbrosis has been reported after the injection of
Gd-EOB-DTPA. However, the clinical experience with Gd-EOB-
DTPA is more limited than with non-speciﬁc gadolinium chelates.
As the other gadolinium chelates, Gd-EOB-DTPA should be used
cautiously in patients with renal insufﬁciency, especially in
patients with a glomerular ﬁltration rate <30 ml/min/1.73m2
[15].
Gd-EOB-DTPA transport in the hepatocytes is mediated by
two different transport systems located at the sinusoidal and can-
alicular membranes of the cell [16]. The contrast agent enters the
hepatocytes through the organic anion transporting polypeptides
OATP1B1 and OATP1B3 which belong to the solute carrier trans-
porter superfamily of the OATPs (SCTO). Following transport
through the hepatocytes, it is excreted into the bile via the mul-
tidrug resistance protein 2 (MRP2), which belongs to the ATP-
binding cassette C (ABCC) transporter subfamily [17–22].
Regarding the function of MRP2, the location of the trans-
porter within the canalicular membrane or inside the hepato-
cytes is important. Thus, MRP2 function is regulated by
transporter retrieval from the canalicular membrane or insertion
into it. It has been reported that oxidative stress induces MRP2
retrieval from the canalicular membranes and causes cholestasis
[23]. In contrast, tauroursodeoxycholic acid inserts MRP2 into the
canalicular membranes and stimulates organic anion secretion
into bile [24].2 vol. 57 j 421–429
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Fig. 2. Classiﬁcation of nodules in liver cirrhosis. (A) Pathological classiﬁcation
of nodules into low grade dysplastic nodules (LGDN), high grade dysplastic
nodules (HGDN), early HCC, and progressed HCC. Early HCCs show a vaguely
nodular appearance and are well differentiated. Progressed HCCs grow in an
expansile fashion with formation of a ﬁbrous capsule and are moderately
differentiated. The differentiation between HGDN and early HCC may be difﬁcult
at histopathological examination. The presence of stromal invasion is a useful
criterion of malignancy. (B) Vascularity of nodules in liver cirrhosis and contrast-
enhanced MR imaging features during the dynamic phase. Unpaired arteries (red
dots) appear in HGDN and more extensively in early HCC. The increase of
unpaired arteries is paralleled by a decrease of portal tracts (diamonds containing
portal venous branch in blue, arterial branch in red and bile duct in orange).
Progressed HCCs only contain unpaired arteries. This evolution explains that
progressed HCCs typically appear hyperintense (Hyper) relative to the liver
parenchyma during the arterial phase at MR imaging (MRIHA) and hypointense
(Hypo) during the portal venous and/or the late dynamic phase (MRIPVE). In
contrast, LGDN appear iso-intense (Iso), whereas HGDN and early HCC have a
variable enhancement (V) depending on their arterial and portal venous supply.
(C) Transporters in nodules of liver cirrhosis and MR imaging features during the
hepatobiliary phase. In early and progressed HCC, OATP1B1/B3 expression is
often decreased (or absent) relative to that of the liver parenchyma (O), whereas
MRP2 expression is often increased (M+). These HCC appear hypointense during
the hepatobiliary phase (MRIHB). In some HCC, OATP expression is increased (O+).
In these HCC, the signal intensity will depend on MRP2 expression. When MRP2
expression is high, the HCCs usually appear hypointense. Hyperintense (or
isointense) HCCs during the hepatobiliary phase are HCCs having high expression
JOURNAL OF HEPATOLOGY
Journal of Hepatology 201Organic acid efﬂux from hepatocytes may also occur through
the sinusoidal membrane because the transport through OATP is
bidirectional and because the sinusoidal membrane also contains
multidrug resistance proteins (MRP3 and MRP4). These efﬂux
pumps are normally expressed at low levels in normal hepato-
cytes but can be upregulated in pathologic conditions, such as
cholestasis [25] (Fig. 1).
The uptake of hepatobiliary contrast agents into hepatocytes
may compete with numerous endogenous compounds and drugs.
OATP1B1 and OATP1B3 transport a broad number of compounds
and competition for uptake may limit Gd-EOB-DTPA uptake by
hepatocytes. When rifampicin is injected before Gd-EOB-DTPA
in normal rats, the antibiotic signiﬁcantly prevents the increase
of liver signal intensity [26]. Such competition between the sub-
strates Gd-EOB-DTPA, rifampicin, and bromosulfophthalein was
also found in human embryonic kidney 293 cells injected with
the human OATP1B1/B3 transporters [18]. In humans, the ﬁrst
interaction to be investigated was that of erythromycin [27].
The co-administration of erythromycin had no effect on GD-
EOB-DTPA-enhanced liver MR imaging.Liver tumor detection
Liver-speciﬁc contrast agents such as Gd-EOB-DTPA were ﬁrst
developed to improve the contrast-to-noise ratio between metas-
tases and liver parenchyma. Lesions with no hepatocytes, such as
metastases, or with less functioning hepatocytes, such as most
HCCs, do not accumulate Gd-EOB-DTPA and appear as low signal
intensity foci against the enhancing high signal parenchyma in
the hepatobiliary phase, thus improving tumor detection. Several
studies have shown that GD-EOB-DTPA-enhanced MR imaging
has a higher sensitivity compared to dynamic contrast-enhanced
CT and MR imaging enhanced with non-speciﬁc contrast agents
for the detection of livermetastases andHCC [13,28–33]. Recently,
the detection of small liver metastases has also been improved by
unenhanced diffusion-weighted MR imaging. This last imaging
sequence tends to have lower spatial resolution than the hepatob-
iliary phase of Gd-EOB-DTPA, and a combination of the two imag-
ing sequences has been recommended for improved diagnostic
efﬁcacy [34]. Regarding therapeutic efﬁcacy, it has been shown
in a largemulticenter trial that GD-EOB-DTPA-enhancedMR imag-
ing changed the surgical strategy in 19 of 131 patients (14.5%) [13].
It should be noted that the time-efﬁciency of GD-EOB-DTPA-
enhanced MR imaging can be improved by performing T2-
weighted and diffusion-weighted MR imaging during the time
period of more than 15 min between the completion of the
dynamic series and the acquisition of the hepatocyte phase
images [34]. This policy is justiﬁed because it has been shown
that the lesion-to-liver contrast was signiﬁcantly higher on T2-
weighted and diffusion-weighted MR images after Gd-EOB-DTPA
and that the apparent diffusion coefﬁcients of focal liver lesions
did not change signiﬁcantly [35,36].of OATP and low expression of MRP2 (M) or HCCs having high expression of
OATP and MRP2 with Gd-EOB-DTPA excretion in pseudoglands.
This ﬁgure illustrates the superiority of GD-EOB-DTPA-enhanced MR imaging
relative to MR imaging enhanced with non-speciﬁc gadolinium chelates in the
differentiation between dysplastic nodules and early HCC because early HCC
appear hypointense during the hepatobiliary phase at GD-EOB-DTPA-enhanced
MR imaging, whereas the enhancement of dysplastic nodules and early HCC
does not differ at MR imaging enhanced with with non-speciﬁc gadolinium
chelates.
2 vol. 57 j 421–429 423
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The improved diagnostic efﬁcacy of Gd-EOB-DTPA relative to
non-speciﬁc gadolinium chelates has to be balanced against its
increased cost. The cost of gadolinium chelates varies among
countries. In several European countries, the cost of Gd-EOB-
DTPA is about three times higher than that of non-speciﬁc gado-
linium chelates [37]. Very few health-economic studies about
Gd-EOB-DTPA are available. In an economic evaluation in
patients with metachronous colorectal liver metastasis, it was
reported that a strategy starting with GD-EOB-DTPA-enhanced
MR imaging was cost saving compared to non-speciﬁc
gadolinium chelate MR imaging by improving pre-operative
planning and decreasing intra-operative changes [37]. More
cost-effectiveness studies based on clinical trial data rather than
on expert opinion are needed in the future.E
Fig. 3. GD-EOB-DTPA-enhanced MR images of HCC in two patients. (A) In the
ﬁrst patient, no lesion is seen during the arterial phase at Gd-EOB-DTPA MR
imaging because of lack of hypervascularity in small HCC. (B) Two small HCCs
(arrow) are seen as hypointense nodules in the right hepatic lobe during the
hepatobiliary phase. (C) In another patient, a HCC of the right liver lobe is
isointense relative to the liver on unenhanced T1-weighted MR image. (D) The
progressed HCC is hypervascular during the arterial phase. (E) The tumor is
hyperintense during the hepatobiliary phase at GD-EOB-DTPA-enhanced MR
imaging.Liver tumor characterization
At MR imaging, tumor characterization is a complex process
based on the analysis of the morphology and signal intensity of
the lesion on the various imaging sequences. Dynamic contrast-
enhanced MR imaging during the arterial, portal venous, and
equilibrium phases has an important role in this context by
showing differences of contrast agent distribution between the
vascular and extravascular spaces of tumors and liver paren-
chyma [1]. GD-EOB-DTPA provides similar information to that
provided by non-speciﬁc gadolinium chelates during the arterial
and venous phases, but enhancement in the equilibrium phase
has contribution from hepatic cellular uptake and contrast in bile
ducts, in addition to contrast in the intravascular and extracellu-
lar spaces. This phase is therefore better referred to as ‘‘late
dynamic phase’’ [4]. Because of increased parenchymal enhance-
ment in this phase, the delayed enhancement traditionally used
to diagnose lesions such as hemangioma and cholangiocarcinoma
(CCC) is altered and may no longer be discernable [38]. The high
parenchymal enhancement at Gd-EOB-DTPA enhancement
explains that hemangiomas may appear hypointense during the
equilibrium and hepatobiliary phases [39].
Hepatocellular carcinomas
At dynamic, contrast-enhanced imaging with non-speciﬁc gado-
linium contrast, hepatocellular carcinomas (HCC) are diagnosed
when arterial hypervascularity and portal venous and/or late
dynamic phase hypointensity or ‘‘washout’’ are demonstrated
[40]. Arterial hypervascularity manifests as increased tumor
enhancement relative to hepatic parenchyma during the arte-
rial-dominant phase, and washout as hypointense tumor relative
to hepatic parenchyma during the venous and/or late dynamic
phases. These characteristic features are observed in most HCCs
and are related to features such as the development of unpaired
arteries, absence of portal vein supply and nodular growth. How-
ever, it has been reported that in nodules 20 mm or smaller, the
sensitivity of MR imaging for the diagnosis of HCC based on these
criteria is only 62% and it is even lower for contrast-enhanced
ultrasound [41]. This low sensitivity is explained by the fact that
early HCCs often lack the characteristic features of HCC. Indeed,
early HCCs often are not hypervascular, have persistent portal
venous blood supply and replacing growth [42].
Interestingly, during the hepatobiliary phase at GD-EOB-
DTPA-enhanced MR imaging, most HCCs, including hypovascular,424 Journal of Hepatology 201early HCC, appear hypointense (Figs. 2 and 3) [43]. Thus, GD-EOB-
DTPA-enhanced MR imaging appears useful for the characteriza-
tion of small HCCs and for their differentiation from dysplastic
nodules and vascular pseudolesions, which usually do not show
this delayed hypointensity [44–47]. In a recent imaging study
including 12 dysplastic nodules, 30 early HCCs and 66 progressed
HCCs, Sano et al. showed that low signal intensity at hepatobiliary
phase GD-EOB-DTPA-enhanced MR imaging had an area under
the receiver operating characteristic curve of 0.98 for the diagno-
sis of HCC. This area was signiﬁcantly larger than that of contrast-
enhanced CT and combined CT during arterial portography and
CT during hepatic arteriography [46].
Because of its high sensitivity in the diagnosis of HCC,
GD-EOB-DTPA-enhanced MR imaging has been recommended
in a recent consensus conference as a method for characterizing2 vol. 57 j 421–429
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Fig. 4. GD-EOB-DTPA-enhanced MR images in a patient with FNH and HA. (A)
On diffusion-weighted MR image, both HA (short arrow) in the right lobe and
FNH (long arrow) in the left lobe are slightly hyperintense. (B) The two lesions are
hypervascular during the arterial phase after Gd-EOB-DTPA injection and cannot
be differentiated. (C and D) Two MR images obtained during the hepatobiliary
phase show that the FNH is isointense (C), whereas the HA is hypointense (D,
slightly lower section).
JOURNAL OF HEPATOLOGYa nodule that has been detected in the cirrhotic liver using ultraso-
nography [47]. However, more data should be obtained about the
speciﬁcity of the hepatobiliary hypointensity sign in prospective
studies that should include patients with other nodules than HCC
and dysplastic nodules. Meanwhile, a hypointense nodule in the
hepatobiliary phase of Gd-EOB-DTPA that is non-hypervascular
in the arterial phase should be regarded as intermediate risk,
whereas one that is hypervascular in the arterial phase is high risk
[47].
The enhancement pattern during the hepatobiliary phase at
GD-EOB-DTPA-enhanced MR imaging has been explained by
OATP and MRP expression. Most HCCs appear hypointense during
that phase because the expression of OATP1B1/B3 is decreased.
When OATP1B1/B3 expression is maintained, the intensity of
HCC depends on the expression of MRP2. In most HCCs, the
expression of MRP2 is high and located on the canalicular mem-
brane of hepatocytes. These HCCs are hypointense. In contrast, 5
– 10% of HCCs are iso- or hyperintense relative to the liver. This
has been related to low MRP2 expression or high MRP2 expres-
sion at the luminal membrane of pseudoglands [48,49] (Figs. 2
and 3).
MRP3 is usually decreased in HCC [50]. It has been observed
that the expression of MRP3 is increased rather than decreased
in hyperintense vs. hypointense HCC [51]. This suggests that
MRP3 expression has little inﬂuence on HCC signal intensity at
GD-EOB-DTPA-enhanced MR imaging.
It has been recently reported that the OATP1B1/B3 expression
is progressively lost in HCCs that gain a biliary phenotype with
worse prognosis [52]. Moreover, it has been shown that MR
imaging hypointensity during the hepatobiliary phase increases
with increasing HCC grade [53]. However, the correlation
between Gd-EOB-DTPA enhancement and tumor grade remainsJournal of Hepatology 201controversial [54]. Further studies are needed to correlate the
enhancement pattern in HCC to the expression of hepatic trans-
porters in the various subtypes of HCC, according to molecular
classiﬁcation [55].
Finally, it has been reported that soranenib, in contrast to sun-
itinib, is a substrate for MRP2 [56]. The relationship between the
signal intensity of HCC at GD-EOB-DTPA-enhanced MR imaging
and resistance to sorafenib is currently unknown.
Benign hepatocellular tumors
The expression of OATP1B1/B3 and MRP2, MRP3 has also been
investigated in focal nodular hyperplasia (FNH) and hepatocellu-
lar adenomas (HA) [57]. Typical FNH is associated with chronic
cholestasis, ductular reaction, and ﬁbrosis. Bile canaliculi are
not connected to bile ducts and bile compounds accumulate
within the lesion. In FNH, OATP1B1/B3 expression is increased,
MRP2 expression is similar to that in the normal liver, while
MRP3 has a low expression. In HA, the OATP1B1/B3 expression
is typically low, MRP2 expression is similar to that in the normal
liver, while MRP3 has a diffuse and high expression.
In clinical studies, FNHs show enhancement during the hepa-
tobiliary phase either similar to or more than liver parenchyma
with low signal intensity of the central scar (Fig. 4) [58]. A case
of FNH-like nodule in liver cirrhosis with lesion hypointensity
during the hepatobiliary phase has been recently reported [59].
This lesion also showed arterial hyperintensity and was misdiag-
nosed as HCC.
The enhancement of HA is variable [60–62]. Most HA are hyp-
ointense during the hepatobiliary phase (Fig. 4). However, some
HA may also take up the contrast agent and appear hyperintense.
As for HCC, further studies are needed to correlate the enhance-
ment pattern in HA to the expression of hepatic transporters in
the various subtypes [63]. Currently, the added value of GD-
EOB-DTPA-enhanced MR imaging relative to dynamic contrast-
enhanced MR imaging with a non-speciﬁc gadolinium chelate
in the differentiation of benign hepatocellular tumors remains
to be proven. The enhancement characteristics of the most fre-
quent liver tumors are shown in Table 1.Bile duct diseases
GD-EOB-DTPA-enhanced cholangiography can be performed dur-
ing the hepatobiliary phase. While the intrahepatic and extrahe-
patic ducts are well seen at 20 min [64], a delay of 30 min after
the injection of Gd-EOB-DTPA is suggested by some authors to
ensure sufﬁcient enhancement of the bile ducts and demonstrate
gallbladder enhancement [65,66]. Biliary enhancement is
affected by hepatic function and has been shown to be weaker
and delayed in the cirrhotic liver [67].
T1-weighted GD-EOB-DTPA-enhanced cholangiography may
add functional information to unenhanced T2-weighted MR chol-
angiography. This may potentially be useful for the detection of
bile duct leaks, the grading of bile duct obstruction, the differen-
tiation between Caroli disease and peribiliary cysts, and the dif-
ferentiation between parenchymal and small bile duct diseases
[65]. However, the visualization of the bile ducts may be poor
or even absent at GD-EOB-DTPA-enhanced cholangiography in
patients with advanced diffuse parenchymal disease or bile duct
obstruction [68]. T2-weighted MR cholangiography should be2 vol. 57 j 421–429 425
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performed before Gd-EOB-DTPA administration due to the T2
shortening effect of enhanced bile which renders the biliary sys-
tem invisible [69].Assessment of liver function
Assessment of liver function is important to determine the
prognosis of patients with chronic liver diseases, and is particu-
larly required in patients with cirrhosis to determine the opti-
mal timing for transplantation or transjugular intrahepatic
portosystemic shunt (TIPS) insertion [70]. Evaluation of total
and regional liver function is also important before major liver
resection to minimize the risk of post-operative liver failure,
especially in patients with cirrhosis or even less advanced dis-
eases such as steatosis, cholestasis, or chemotherapy toxicity
[71,72]. Indocyanin green (ICG) clearance and hepatic scintigra-
phy with technetium-99m mebrofenin (99mTc-mebrofenin) have
been proposed for assessing liver function. The organic anion
99mTc-mebrofenin is a substrate of OATP1B1/B3, whereas ICG
is a substrate of OATP1B3 and sodium taurocholate-cotransport-
ing polypeptide (NTCP). Both ICG and mebrofenin are excreted
in the bile by MRP2 without undergoing biotransformation
[73,74].
Assessment of liver function at GD-EOB-DTPA-enhanced MR
imaging may be an alternative to ICG clearance and hepatic scin-
tigraphy with 99mTc-mebrofenin. Hepatic extraction fraction of
Gd-EOB-DTPA has been shown to correlate with ICG clearance
in rabbits and liver-spleen contrast to noise ratio at GD-EOB-
DTPA-enhanced MR imaging has been shown to correlate with
ICG clearance in patients [75,76]. The advantages of GD-EOB-
DTPA-enhanced MR imaging include absence of radiation, com-
bined anatomical and functional assessment, and the ability to
quantitatively assess hepatic perfusion and function [77]. A pre-
liminary study in rats to evaluate liver ﬁbrosis showed a good
correlation between advanced ﬁbrosis and the signal-intensity
time course of GD-EOB-DTPA-enhanced MR imaging [78].
Decreased enhancement and increased enhancement time are
attributed to slower hepatocyte uptake due to lower OATP1 activ-
ity, and rapid elimination due to increased MRP2 activity which is
upregulated in the cirrhotic liver [79].
Several issues need to be taken into account when performing
pharmacokinetic analysis of liver enhancement at GD-EOB-DTPA-
enhanced MR imaging. These include the lack of linear
relationship between signal intensity of liver and contrast agent
concentration, and the differing relaxivity of Gd-EOB-DTPA in
water, blood and liver [80]; the need to incorporate all factors
that inﬂuence hepatic clearance of contrast agents such as blood
ﬂow, transmembrane barriers and the presence of other drugs
metabolized in the liver [81,82]; and lastly the complexity of
transporter regulation in hepatocytes including the inter-individ-
ual variability of transporter expression and the saturation of the
transport systems at high concentrations of the contrast agents
[83–85].Conclusions
Despite the difﬁculties in quantiﬁcation of liver function,
GD-EOB-DTPA-enhanced MR imaging offers a unique opportunity
to combine qualitative and quantitative morphological and426 Journal of Hepatology 201functional information that may improve the assessment of focal
liver lesions and diffuse liver diseases and probe liver function.
Key Points 
• 
has 50% hepatocytic uptake and biliary excretion in the 
normal liver
• The transport of Gd-EOB-DTPA in the hepatocyte 
mainly occurs through OATP1B1/B3 transporters at 
the sinusoidal membrane and MRP2 at the canalicular 
membrane
• For liver imaging, Gd-EOB-DTPA behaves similarly to 
the arterial, portal venous and late dynamic phases, 
because both contrast agents are mainly located in 
the vascular and extravascular spaces during these 
phases, but Gd-EOB-DTPA adds information during the 
hepatobiliary phase (20 min after injection) because it is 
mainly located within hepatocytes and bile ducts at that 
time
• During the hepatobiliary phase, the high contrast 
between the hepatic parenchyma that contains Gd-
EOB-DTPA and liver metastases that do not contain the 
contrast agent improves the detection of these tumors
• Hepatocellular tumors take up variable amounts of 
Gd-EOB-DTPA, which are related to their expression of 
OATP1B1/B3 and MRP2
• The detection and characterization of HCC, especially 
early HCC, is improved at Gd-EOB-DTPA -enhanced MR 
imaging because most of these lesions are hypointense 
during the hepatobiliary phase even if they do not show 
the characteristic features of arterial hypervascularity 
and washout during the portal venous and/or late 
dynamic phase
• The HCC hypointensity during the hepatobiliary phase 
is explained by decreased expression of OATP with 
high expression of MRP2. In contrast, some HCC are 
iso or hyperintense during that phase because of high 
OATP expression with decreased MRP2 expression or 
high OATP expression with high expression of MRP2 in 
luminal membranes of pseudoglands
• FNH is iso or hyperintense during the hepatobiliary 
phase, whereas HA have variable signal, most of them 
being hypointense
• The enhancement of the liver at Gd-EOB-DTPA 
enhanced MR imaging depends mainly on liver 
perfusion, vascular permeability, extracellular diffusion 
and hepatocyte transporter expression. These functions 
DTPA - enhanced MR imaging has the potential to provide 
quantitative information about liver perfusion and 
function
• Combined anatomical and functional information on focal 
and diffuse liver diseases can be obtained at Gd-EOB-
DTPA - enhanced MR imaging
Gd-EOB-DTPA is a liver-specific MR contrast agent that
a non-specific extracellular gadolinium chelate during
being modified during diffuse liver disease, Gd-EOB-2 vol. 57 j 421–429
Table 1. Enhancement characteristics of the most frequent liver tumors.
Arterial 
phase
Portal venous 
phase
Equilibrium 
phase
Hepatobiliary 
phase
Hemangioma Iso-hypo 
(peripheral nodular enhancement)
Iso-hypo 
(peripheral nodular enhancement)
Iso-hypo Hypo
FNH Hyper Iso Iso Iso-hyper
Variable Hypo or hyper
nhancement) Hypo Hypo
Hypo Hypo or hyper
ostly hypo Variable, mostly hypo Hypo
JOURNAL OF HEPATOLOGYCCC Hypo or hyper Variable, mAdenoma Variable Variable
Metastasis Hypo (ring enhancement) or hyper Hypo (ring e
HCC Hyper or iso, hypo HypoConﬂict of interest
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